EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis

Yue Li, Congshan Jiang, Wenhua Zhu, Shemin Lu, Hongchuan Yu, Liesu Meng iD

Science Progress · 2024

DOI: 10.1177/00368504241247402 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Science Progress, 2024. Verfasst von Yue Li und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Regional Children's Medical Center (Northwest), Key Laboratory of Precision Medicine to Pediatric Diseases of Shaanxi Province, Xi'an Key La…. Hauptthemen laut MEDLINE: Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Xi'an Children's Hospital, Natural Science Foundation of Shaanxi Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis is a chronic and progressive interstitial lung disease with a poor prognosis. Idiopathic pulmonary fibrosis is characterized by repeated alveolar epithelial damage leading to abnormal repair. The intercellular microenvironment is disturbed, leading to continuous activation of fibroblasts and myofibroblasts, deposition of extracellular matrix, and ultimately fibrosis. Moreover, pulmonary fibrosis was also found as a COVID-19 complication. Currently, two drugs, pirfenidone and nintedanib, are approved for clinical therapy worldwide. However, they can merely slow the disease's progression rather than rescue it. These two drugs have other limitations, such as lack of efficacy, adverse effects, and poor pharmacokinetics. Consequently, a growing number of molecular therapies have been actively developed. Treatment options for IPF are becoming increasingly available. This article reviews the research platform, including cell and animal models involved in molecular therapy studies of idiopathic pulmonary fibrosis as well as the promising therapeutic targets and their development progress during clinical trials. The former includes patient case/control studies, cell models, and animal models. The latter includes transforming growth factor-beta, vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, lysophosphatidic acid, interleukin-13, Rho-associated coiled-coil forming protein kinase family, and Janus kinases/signal transducers and activators of transcription pathway. We mainly focused on the therapeutic targets that have not only entered clinical trials but were publicly published with their clinical outcomes. Moreover, this work provides an outlook on some promising targets for further validation of their possibilities to cure the disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Idiopathic Pulmonary FibrosisHumansAnimalsMolecular Targeted TherapyPyridonesIndolesCOVID-19Disease Models, Animal

Stichwörter der Autor:innen

Idiopathic pulmonary fibrosismolecular therapytherapeutic target

Substanzen

nintedanibpirfenidonePyridonesIndoles

Autor:innen und Institutionen

  • National Regional Children's Medical Center (Northwest), Key Laboratory of Precision Medicine to Pediatric Diseases of Shaanxi Province, Xi'an Key Laboratory of Children's Health and Diseases, Shaanxi Institute for Pedi…
  • First Department of Respiratory Diseases, Xi'an Children's Hospital, Affiliated Children's Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, People's Republic of China.
  • Institute of Molecular and Translational Medicine (IMTM), and Department of Biochemistry and Molecular Biology, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi, People's Republic of China.
  • Key Laboratory of Environment and Genes Related to Diseases, Xi'an Jiaotong University, Ministry of Education, Xi'an, Shaanxi, People's Republic of China.

ORCID-Profile: Liesu Meng

Förderung

  • National Natural Science Foundation of China
  • Xi'an Children's Hospital
  • Natural Science Foundation of Shaanxi Province

Zitieren

APA

Li, Y., Jiang, C., Zhu, W., Lu, S., Yu, H., & Meng, L. (2024). Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis. Science Progress. https://doi.org/10.1177/00368504241247402

Vancouver

Li Y, Jiang C, Zhu W, Lu S, Yu H, Meng L. Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis. Science Progress. 2024. doi:10.1177/00368504241247402

BibTeX
@article{Li2024,
  author = {Li, Yue and Jiang, Congshan and Zhu, Wenhua and Lu, Shemin and Yu, Hongchuan and Meng, Liesu},
  title = {Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis},
  journal = {Science Progress},
  year = {2024},
  doi = {10.1177/00368504241247402}
}
Kostenlos starten →